Bengaluru‑based agri‑processing platform Agrizy announced the launch of an in‑house Gen‑AI formulation studio that promises to slash development cycles and costs for food, beverage and wellness brands.

The studio, described by co‑founder and CEO Vicky Dodani, harnesses machine‑learning models trained on historical failure data to deliver a deterministic layer that trims the number of formulation iterations. The company says the system can cut manual options by more than 90 percent and return ingredient lists, per‑kg cost, regulatory constraints for multiple geographies and total production cost in a single run.

Agrizy’s move is part of a broader effort to modernise its contract development and manufacturing organisation (CDMO) services. The firm recently overhauled its research and development laboratory, now focused on three core product categories: food and beverages, snacks and savouries, and functional protein bars. Senior formulation scientists have joined the team to support these areas.

The platform serves a diverse customer base that spans India and abroad, with a particular emphasis on European markets. “Today, we are supplying our products to more than 20 countries. Our major products to Europe are fruits and vegetables,” Dodani said. In addition to fresh produce, Agrizy exports customised pulses, purees and ready‑to‑eat items such as gherkins and baby corn.

In the food‑and‑beverage segment, Agrizy works with a range of spices, plant ingredients and extracts. The company has developed higher‑bioavailability formulations, including liposomal versions of curcumin and ashwagandha extracts. These wellness ingredients are used in nutraceuticals and cosmetics, while the food‑formulation arm customises snacks, savouries, ready‑to‑drink beverages and breakfast cereals for brands on a B2B basis.

Since its founding in September 2021, Agrizy has launched 25–30 products a year using the Gen‑AI studio and now boasts more than 100 products in its portfolio. The company sources raw materials from clusters in Kerala, Andhra Pradesh, Telangana, Karnataka and the North‑East, and processes them locally.

Agrizy does not own processing assets; instead it partners with micro, small and medium‑enterprise (MSME) processors to increase their capacity. Its quality‑assurance framework incorporates Internet‑of‑Things (IoT) devices and computer‑vision technology to automate inspections and ensure compliance with maximum residue limits (MRL) required by European buyers. The platform also includes a matchmaking engine that connects customers with qualified processors, streamlining the supply‑chain match‑making process.

The company has filed a patent for a single‑solvent extraction process that aims to provide consistency across batches. It also claims that liposomal encapsulation can increase the bioavailability of ingredients such as curcumin by up to six times.

Agrizy has filed trademarks for 22 products and reports that exports account for 5–10 percent of its revenue. The firm is growing at a 60 percent compound annual growth rate (CAGR) and plans to expand its global footprint, focusing on food‑and‑beverage exports, research and development, and potential synergies with suppliers in Southeast Asia and Africa.

In a recent funding round, Agrizy raised $9.8 million in a Series A led by Accion and Omnivore, with participation from Capria Ventures, Thai Wah Ventures and existing investor Ankur Capital. The capital is expected to support the expansion of its AI platform, laboratory capabilities and international supply‑chain network.

Agrizy’s Gen‑AI studio represents a significant step toward integrating advanced data analytics into agri‑processing. While the company has yet to publish independent third‑party validation of the claimed cost and time savings, its platform is positioned to serve a growing market for rapid, compliant product development in the food, beverage and wellness sectors.

The next milestone for Agrizy will be the launch of additional product categories and the scaling of its matchmaking engine to cover more regions. Investors and partners will be watching the company’s upcoming quarterly results and any further regulatory approvals that may affect its export operations.